PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity

PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity

Summary: Cancer immunotherapies have demonstrated remarkable success; however, the majority of patients do not respond or develop resistance. Here, we conduct epigenetic gene-targeted CRISPR-Cas9 screens to identify epigenomic factors that limit CD8+ T cell-mediated anti-tumor immunity. We identify...

Full description

Bibliographic Details
Main Authors: Tirta M. Djajawi, Lizzy Pijpers, Akash Srivaths, David Chisanga, Kok Fei Chan, Simon J. Hogg, Liam Neil, Sarahi Mendoza Rivera, Nenad Bartonicek, Sarah L. Ellis, Terry C.C. Lim Kam Sian, Pouya Faridi, Yang Liao, Bhupinder Pal, Andreas Behren, Wei Shi, Stephin J. Vervoort, Ricky W. Johnstone, Conor J. Kearney
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Cell Reports
Subjects:
CP: Cancer
CP: Immunology
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124724001591

Internet

http://www.sciencedirect.com/science/article/pii/S2211124724001591

Similar Items